HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Earle W. Wilkins, Jr. Noah C. Choi Douglas J. Mathisen Hermes C. Grillo Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hilgenberg, A. D. Articles by Grillo, H. C. Search for Related Content PubMed PubMed Citation Articles by Hilgenberg, A. D. Articles by Grillo, H. C.

Ann Thorac Surg 1988;45:357-363
© 1988 The Society of Thoracic Surgeons

---

Articles

Preoperative chemotherapy, surgical resection, and selective postoperative therapy for squamous cell carcinoma of the esophagus

From the Surgical, Medical, and Radiation Medicine Services at the Massachusetts G General Hospital, Boston, MA, USA

^_* Address reprint requests to Dr. Hilgenberg, Massachusetts General Hospital, Boston, MA 02114.

In an attempt to improve on the long-term survival rate of patients with esophageal squamous cell carcinoma, we designed a study in which treatment included preoperative chemotherapy with fluorouracil and cisplatin, surgical resection, and selective postoperative chemotherapy or radiation therapy. Between 1981 and 1986, 35 patients with potentially resectable lesions were entered into the study. After chemotherapy, 13 of 35 patients (37%) had a complete clinical response, 7 (20%) had a partial response, and 15 (43%) had no response. One patient sustained a serious toxic reaction (renal failure). Twenty-seven patients underwent surgical resection, with 1 hospital death (3.7%). Selective postoperative radiotherapy or chemotherapy was administered to 69%. The actuarial survival of all resected patients at 42 months was 54% (standard error, 10%). Multivariate analysis showed significant factors associated with 3-year survival were: (1) complete clinical response to chemotherapy; (2) absence of wall penetration in the specimen; and (3) microscopic or no disease in the specimen. We conclude that this multimodality treatment method improves the intermediate-term survival of patients with squamous cell carcinoma of the esophagus.

This article has been cited by other articles:

				A. Herskovic, W. Russell, M. Liptay, M. J. Fidler, and M. Al-Sarraf Esophageal carcinoma advances in treatment results for locally advanced disease: review Ann. Onc., October 14, 2011; (2011) mdr433v1. [Abstract] [Full Text] [PDF]

				Y. OSAKA, M. SHINOHARA, S. HOSHINO, T. OGATA, Y. TAKAGI, A. TSUCHIDA, and T. AOKI Phase II Study of Combined Chemotherapy with Docetaxel, CDDP and 5-FU for Highly Advanced Esophageal Cancer Anticancer Res, February 1, 2011; 31(2): 633 - 638. [Abstract] [Full Text] [PDF]

				W. H. Allum, S. P. Stenning, J. Bancewicz, P. I. Clark, and R. E. Langley Long-Term Results of a Randomized Trial of Surgery With or Without Preoperative Chemotherapy in Esophageal Cancer J. Clin. Oncol., October 20, 2009; 27(30): 5062 - 5067. [Abstract] [Full Text] [PDF]

				M. Koshy, N. Esiashvilli, J. C. Landry, C. R. Thomas Jr., and R. H. Matthews Multiple Management Modalities in Esophageal Cancer: Combined Modality Management Approaches Oncologist, April 1, 2004; 9(2): 147 - 159. [Abstract] [Full Text] [PDF]

				M. B. Polee, H. W. Tilanus, F. A. L. M. Eskens, R. Hoekstra, M. E. L. Van der Burg, P. D. Siersema, G. Stoter, and A. Van der Gaast Phase II study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagus Ann. Onc., August 1, 2003; 14(8): 1253 - 1257. [Abstract] [Full Text] [PDF]

				K. Hayashi, N. Ando, H. Watanabe, H. Ide, K. Nagai, N. Aoyama, W. Takiyama, K. Ishida, K. Isono, H. Makuuchi, et al. Phase II Evaluation of Protracted Infusion of Cisplatin and 5-Fluorouracil in Advanced Squamous Cell Carcinoma of the Esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407) Jpn. J. Clin. Oncol., September 1, 2001; 31(9): 419 - 423. [Abstract] [Full Text] [PDF]

				E. Laterza, C. Griso, U. S. Urso, G. de' Manzoni, M. Malago, C. Oliani, and C. Cordiano Induction therapy for squamous carcinoma of thoracic esophagus Ann. Thorac. Surg., May 1, 1994; 57(5): 1126 - 1132. [Abstract] [PDF]

				S. J. Hoff, J. R. Stewart, J. L. Sawyers, M. J. Murray, W. H. Merrill, R. B. Adkins, and D. H. Johnson Preliminary results with neoadjuvant therapy and resection for esophageal carcinoma Ann. Thorac. Surg., August 1, 1993; 56(2): 282 - 287. [Abstract] [PDF]

				T. W. Rice, G. A. Boyce, M. V. Sivak, D. J. Adelstein, and T. J. Kirby Esophageal carcinoma: Esophageal ultrasound assessment of preoperative chemotherapy Ann. Thorac. Surg., June 1, 1992; 53(6): 972 - 977. [Abstract] [PDF]

				K. A. Mansour, A. L. Picone, and J. J. Coleman III Surgery for high cervical esophageal carcinoma: Experience with 11 patients Ann. Thorac. Surg., April 1, 1990; 49(4): 597 - 602. [Abstract] [PDF]

				M. B. Orringer, A. A. Forastiere, C. Perez-Tamayo, S. Urba, B. J. Takasugi, and J. Bromberg Chemotherapy and radiation therapy before transhiatal esophagectomy for esophageal carcinoma Ann. Thorac. Surg., March 1, 1990; 49(3): 348 - 355. [Abstract] [PDF]

				K. A. Mansour and R. S. Downey Esophageal carcinoma: Surgery without preoperative adjuvant chemotherapy Ann. Thorac. Surg., August 1, 1989; 48(2): 201 - 204. [Abstract] [PDF]

				V. L. Lackey, M. T. Reagan, R. A. Smith, and W. J. Anderson Neoadjuvant therapy of squamous cell carcinoma of the esophagus: Role of resection and benefit in partial responders Ann. Thorac. Surg., August 1, 1989; 48(2): 218 - 221. [Abstract] [PDF]

				W. S. Pierce Cardiothoracic Surgery JAMA, May 19, 1989; 261(19): 2827 - 2829. [Abstract] [PDF]